Effectiveness and safety of a biosimilar-to-biosimilar switch of the TNF inhibitor etanercept in patients with chronic inflammatory rheumatic diseases

BACKGROUND: Biosimilar disease-modifying anti-rheumatic drugs (bsDMARDs) has created a financial incentive to encourage switching to cheaper products. OBJECTIVES: We aim to study the effectiveness and safety of a non-medical bsDMARD-to-bsDMARD switch from originator etanercept (ETN) to bsDMARD ETN (...

Descripción completa

Detalles Bibliográficos
Autores principales: Kiltz, Uta, Tsiami, Styliani, Baraliakos, Xenofon, Andreica, Ioana, Kiefer, David, Braun, Jürgen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9424877/
https://www.ncbi.nlm.nih.gov/pubmed/36051634
http://dx.doi.org/10.1177/1759720X221119593

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9424877/
https://www.ncbi.nlm.nih.gov/pubmed/36051634
http://dx.doi.org/10.1177/1759720X221119593

Ejemplares similares